Table 2.
Cox regression models of the impact of TA-TMA on overall survival and renal failure/need for dialysis, using TA-TMA as time-dependent covariate
| Outcome | Level | N | HR | Lower 95% CI | Upper 95% CI | Pwp | Overall p-value |
|---|---|---|---|---|---|---|---|
| Overall survival | <0.001 | ||||||
| No TA-TMA | 22944 | 1.00 | |||||
| TA-TMA, all patients | 653 | 3.09 | 2.79 | 16.34 | <0.001 | ||
| TA-TMA, no plasmapheresis | 499 | 2.47 | 2.20 | 2.78 | <0.001 | ||
| TA-TMA, plasmapheresis | 154 | 4.14 | 3.44 | 4.99 | <0.001 | ||
| Need for RRT | <0.001 | ||||||
| No TA-TMA | 21939 | 1.00 | |||||
| TA-TMA, all patients | 619 | 7.12 | 5.74 | 311.64 | <0.001 | ||
| TA-TMA, no plasmapheresis | 467 | 3.81 | 2.87 | 5.05 | <0.001 | ||
| TA-TMA, plasmapheresis | 152 | 14.92 | 10.90 | 20.42 | <0.001 |
Abbreviations: HR - hazard ratio, CI - confidence interval, TA-TMA - transplant associated thrombotic microangiopathy; N - number; RRT - renal replacement therapy, pwp - pairwise p-value
*
Adjusted for age, race, KPS, kidney function at baseline, disease, disease status, donor type, prior auto-HCT, use of ATG/ alemtuzumab, year of TX, GVHD prophylaxis, conditioning, and graft type.